1. Signaling Pathways
  2. PI3K/Akt/mTOR
    Stem Cell/Wnt
  3. GSK-3

GSK-3 (糖原合成酶激酶3)

Glycogen synthase kinase 3 (GSK-3) is a multifunctional serine/threonine kinase consisting of two isoforms, alpha and beta. GSK-3 is a key regulator of numerous signalling pathways, including cellular responses to Wnt, receptor tyrosine kinases and G-protein-coupled receptors and is involved in a wide range of cellular processes, ranging from glycogen metabolism to cell cycle regulation and proliferation. GSK-3 is unusual in that it is normally active in cells and is primarily regulated through inhibition of its activity.

GSK-3 亚型特异性产品:

  • GSK-3

  • GSK-3α

  • GSK-3β

目录号 产品名 作用方式 纯度
  • HY-10182
    CHIR-99021 Inhibitor ≥98.0%
    CHIR-99021 (CT99021) 是一种有效的选择性 GSK-3α/β 抑制剂,IC50 为 10 nM 和 6.7 nM。CHIR-99021 对 GSK-3 的选择性比 CDC2,ERK2 和其他蛋白激酶高 500 倍以上。CHIR-99021 还是一种有效的 Wnt/β-catenin 信号通路激活剂。CHIR-99021 可增强小鼠和人类胚胎干细胞的自我更新。CHIR-99021 能诱导细胞自噬 (autophagy)。
  • HY-12012
    SB 216763 Inhibitor 99.30%
    SB 216763是有效,选择性和ATP竞争性的 GSK-3 抑制剂,抑制GSK-3α和GSK-3β的 IC50 为34.3 nM。
  • HY-16294
    LY2090314 Inhibitor 99.01%
    LY2090314 是一种有效的 GSK-3 抑制剂,抑制 GSK-3α 和 GSK-3β,IC50 值分别为 1.5 nM 和 0.9 nM。
  • HY-14872
    Tideglusib Inhibitor 99.66%
    Tideglusib (NP031112) 是一种不可逆的 GSK-3 抑制剂,抑制 GSK-3βWTGSK-3βC199AIC50 分别为5 nM,60 nM。
  • HY-10590
    TWS119 Inhibitor ≥98.0%
    TWS119 是一种 GSK-3β 特异性抑制剂,IC50 值为 30 nM,同时可激活 wnt/β-catenin 信号通路。
  • HY-137894A
    PF-07104091 hydrate Inhibitor 99.26%
    PF-07104091 hydrate 是一种高效选择性的 CDK2/cyclin E1GSK3β 抑制剂,其 Ki 分别为 1.16 和 537.81 nM。PF-07104091 hydrate 对细胞周期素扩增的癌症具有抗肿瘤活性,来自专利 WO2020157652A2。
  • HY-117025A
    Manzamine A hydrochloride Inhibitor 99.29%
    Manzamine A hydrochloride 是一种口服活性 β-carboline 生物碱,抑制 GSK-3βCDK-5IC50 值为 10.2 μM 和 1.5 μM。Manzamine A hydrochloride 靶向胰腺癌细胞的 vacuolar ATPases 并抑制自噬 (autophagy)。Manzamine A hydrochloride 具有抗疟和抗癌活性。Manzamine A hydrochloride 通过对 HSV-1 具有较强的活性。
  • HY-137894
    PF-07104091 Inhibitor
    PF-07104091 是一种高效选择性的 CDK2/cyclin E1GSK3β 抑制剂,其 Ki 分别为 1.16 和 537.81 nM。PF-07104091 对细胞周期素扩增的癌症具有抗肿瘤活性,来自专利 WO2020157652A2。
  • HY-10512
    AR-A014418 Inhibitor 99.49%
    AR-A014418 是一种有效,选择性,ATP 竞争性的 GSK3β 抑制剂 (IC50=104 nM; Ki=38 nM)。
  • HY-10182A
    CHIR-99021 monohydrochloride Inhibitor 99.93%
    CHIR-99021 monohydrochloride (CT99021 monohydrochloride) 是一种有效的选择性 GSK-3α/β 抑制剂,IC50 为 10 nM 和 6.7 nM。CHIR-99021 monohydrochloride 对 GSK-3 的选择性比 CDC2,ERK2 和其他蛋白激酶高 500 倍以上。CHIR-99021 monohydrochloride 还是一种有效的 Wnt/β-catenin 信号通路激活剂。CHIR-99021 monohydrochloride 可增强小鼠和人类胚胎干细胞的自我更新。CHIR-99021 monohydrochloride 能诱导细胞自噬 (autophagy)。
  • HY-11012
    TDZD-8 Inhibitor 99.76%
    TDZD-8 是 GSK-3β 的抑制剂,IC50 为 2 μM;TDZD-8 对 Cdk-1/cyclin B,CK-II,PKA 和 PKC 的作用较弱,IC50 值均 >100 μM。
  • HY-10580
    GSK 3 Inhibitor IX Inhibitor ≥98.0%
    GSK 3 Inhibitor IX (6-Bromoindirubin-3'-oxime; BIO) 是一种有效的,选择性的,可逆的,ATP 竞争性的 GSK-3α/βCDK1-cyclinB 复合体抑制剂,能够抑制 (GSK-3α/β)/CDK1/CDK5 的活性,IC50 值分别为 5 nM/320 nM/83 nM。
  • HY-12302
    Kenpaullone Inhibitor 98.01%
    Kenpaullone 是一种有效的 CDK1/cyclin BGSK-3β 抑制剂,IC50 值分别为 0.4 μM 和 23 nM,同时可抑制 CDK2/cyclin A,CDK2/cyclin E 和 CDK5/p25 的活性,IC50 值分别为 0.68 μM,7.5 μM 和 0.85 μM。Kenpaullone,一种 KLF4 的小分子抑制剂,在体外降低乳腺癌干细胞的自我更新和细胞活力。
  • HY-10182B
    CHIR-99021 trihydrochloride Inhibitor 98.01%
    CHIR-99021 trihydrochloride (CT99021 trihydrochloride) 是一种有效的选择性 GSK-3α/β 抑制剂,IC50 为 10 nM 和 6.7 nM。CHIR-99021 trihydrochloride 对 GSK-3 的选择性比 CDC2,ERK2 和其他蛋白激酶高 500 倍以上。CHIR-99021 trihydrochloride 还是一种有效的 Wnt/β-catenin 信号通路激活剂。CHIR-99021 trihydrochloride 可增强小鼠和人类胚胎干细胞的自我更新。CHIR-99021 trihydrochloride 能诱导细胞自噬 (autophagy)。
  • HY-13862
    AZD1080 Inhibitor ≥98.0%
    AZD1080 是一种有效的选择性 GSK3 抑制剂。AZD1080 抑制重组人 GSK3αGSK3βpKi (IC50) 分别为 8.2 (6.9 nM) 和 7.5 (31 nM)。
  • HY-B0320A
    Cromolyn sodium Inhibitor 99.10%
    Cromolyn sodium (Disodium Cromoglycate; FPL-670) 是抗过敏化合物。Cromolyn sodium 是一种 GSK-3β 抑制剂,IC50 为 2.0 µM。
  • HY-13076
    CHIR-98014 Inhibitor ≥98.0%
    CHIR-98014 是一种有效的,细胞通透的 GSK-3 抑制剂,可抑制 GSK-3αGSK-3β 的活性,IC50 值分别为 0.65 和 0.58 nM;CHIR-98014 对 cdc2 和 erk2 的作用较弱。
  • HY-113914
    9-ING-41 Inhibitor 99.32%
    9-ING-41 是一种基于马来酰亚胺的 ATP 竞争性和选择性的糖原合酶激酶-3β (GSK-3β) 抑制剂,IC50 为 0.71 μM。9-ING-41 显著导致癌细胞的细胞周期停滞,自噬和凋亡。9-ING-41 具有抗癌活性,并具有增强化疗药物抗肿瘤作用的潜力。
  • HY-10014
    R547 Inhibitor 99.66%
    R547 是一种高效、选择性的,口服有效的 ATP 竞争性的 CDK 抑制剂,对 CDK1/cyclin B、 CDK2/cyclin E 和 CDK4/cyclin D1 作用的 Ki 值分别为 2 nM、3 nM、1 nM。
  • HY-116830
    BRD0705 Inhibitor 98.41%
    BRD0705 是一种有效的,具有旁系选择性和口服活性的 GSK3α 抑制剂,IC50 为 66 nM,Kd 为 4.8 μM。 BRD0705 与 GSK3β (IC50 为 515 nM) 相比,对 GSK3α 的选择性更高 (8 倍)。BRD0705 可用于急性髓细胞性白血病的研究。

Glycogen synthase kinase 3 (GSK-3) is a multifunctional serine/threonine kinase found in all eukaryotes. GSK-3 is one of the few signaling mediators that play central roles in a diverse range of signaling pathways, including those activated by Wnt, PI3K, growth factors, cytokines, and ligands for G protein-coupled receptors. The PI3K pathway is known for regulating metabolism, cell growth, and cell survival. The PI3K activity is stimulated by diverse oncogenes and growth factor receptors. PI3K-mediated production of PIP3 leads to the activation of Akt. The activation of Akt leads to the phosphorylation of GSK-3, which is active in resting cells, but is inactivated by the phosphorylation. The GSK-3 has been linked to the regulation of an assembly of transcription factors, including β-catenin, NF-κB, c-Jun, CREB, and STAT. Thus, the altered activity of GSK-3 causes various effects on cytokine expression. 


In the absence of Wnt signaling, β-catenin is phosphorylated by CK1 and GSK-3. This phosphorylation leads to recognition by β-TrCP, leading to the ubiquitylation of β-catenin and degradation by the proteasome. Upon binding of a lipid-modified Wnt protein to the receptor complex, a signaling cascade is initiated. LRP is phosphorylated by CK1/CK2 and GSK-3, and Axin is recruited to the plasma membrane. The kinases in the β-catenin destruction complex are inactivated and β-catenin translocates to the nucleus to form an active transcription factor complex with TCF, leading to transcription of a large set of target genes.


Some endogenous growth factors could bind to and activate the tyrosine kinase receptor. This facilitates the recruitment of other proteins (SHC, SOS), which results in the activation of the ERK-MAPK cascade and the inhibition of GSK-3. GSK-3 exerts many cellular effects: it regulates cytoskeletal proteins, and is important in determining cell survival/cell death. GSK-3 has also been identified as a target for the actions of lithium. GSK-3 can inhibit glycogen synthase, the enzyme that catalyzes the transfer of glucose from UDPG to glycogen[1][2].



[1]. Brenner D, et al. Regulation of tumour necrosis factor signalling: live or let die.Nat Rev Immunol. 2015 Jun;15(6):362-74. 
[2]. Conrad M, et al. Regulated necrosis: disease relevance and therapeutic opportunities.Nat Rev Drug Discov. 2016 May;15(5):348-66. 

Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.